Zhongtai Securities Co.Ltd(600918) small and medium-sized market research team conducted corresponding sorting and Research on the companies approved by the CSRC for IPO registration in the latest week of gem and science and Innovation Board (202204.04202204.11), and launched the weekly special research report on new shares. This weekly report involves 2 enterprises to be issued on the science and innovation board and 2 enterprises to be issued on the gem:
Kechuang board:
Yifang Biology (a21038. SH): the company is an innovative drug R & D enterprise, focusing on major diseases such as tumors and metabolic diseases, and providing patients with safe, effective and affordable treatment schemes. The company's main products are in the research and development stage and have not yet been sold on the market, but the company has a strong competitive advantage of leading clinical progress and high drug resistance of products. At present, there is no consistent profit expectation in the market. With the increase of drug demand and the gradual opening of market space, and the raised investment projects will further enhance the company's operating efficiency and R & D level, the company is expected to improve its industry strength and market position.
Yuncong Technology (a04529. SH): the company is China's leading artificial intelligence enterprise providing efficient man-machine cooperative operating system and industry solutions. The company's revenue grew steadily. The compound annual growth rate of the company's operating revenue from 2018 to 2020 was 24.9%. In the first half of 2021, the company achieved a revenue of 450 million yuan, an increase of 105.70% over the same period last year. At present, the company has 258 invention patents, with high R & D level and technical level, and has certain competitive advantages. In the future, with the further development of national favorable policies, the improvement of computing power brought by "counting from the east to the west" and the progress of artificial intelligence technology, artificial intelligence enterprises will usher in a climax of development. As one of the "Ai four dragons", the company is expected to take the lead in benefiting. In addition, with the progress of the company's fund-raising projects, the company's technical advantages will be further strengthened and the company's market position will continue to improve.
Gem:
Huaru Technology (a17347. SZ): the company is a leading private enterprise with military simulation as its main business in China. The compound growth rates of the company's operating revenue and net profit attributable to the parent company from 2017 to 2021 were 40.26% and 25.36% respectively. The military simulation industry has a broad development space. The procurement mode of military products has gradually changed from the traditional directional procurement to the market-oriented procurement mode. Private enterprises will play an increasingly important role in the professional market and their market position will be steadily improved; The company's technical strength is well recognized and the product system covers all areas. After the successful implementation of the fund-raising project, it is conducive to further expand the company's business scale and strengthen the company's R & D capability. The company will have an advantage in the future market competition.
Tengya metalworking (a20739. SZ): the company is mainly engaged in the R & D, production and sales of nail shooting and fastening equipment and building hardware products. The compound annual growth rates of the company's revenue and net profit from 2018 to 2020 were 14.07% and 30.98% respectively, with good development capacity. There is a certain market demand in the nail shooting fastening equipment and construction hardware products industry. In the future, the company's investment in nail shooting fastening equipment and construction hardware products will continue to increase, and the raised investment projects will significantly improve the company's production and R & D capacity, improve product capacity and enhance core competitiveness. The company is expected to further improve its industry strength and market position.
Risk tips: 1) the corresponding companies still have the risk of failure to be listed due to special events; 2) The research is only based on the prospectus (Registration draft) and other public materials of the corresponding company, which can not fully reflect the latest situation of the company.
